WHO Condemns Unethical US-Funded Hepatitis B Trial in Guinea-Bissau

The World Health Organization (WHO) has issued a stern statement expressing significant ethical and scientific concerns regarding a planned US-funded randomized controlled trial (RCT) for the hepatitis B birth dose vaccine in Guinea-Bissau. Published on February 13, 2026, the WHO statement highlights that the proposed study, which intends to enroll 14,000 newborns, includes a control group that would not receive the vaccine at birth, a move deemed highly unethical given the vaccine's proven efficacy and the high prevalence of hepatitis B in Guinea-Bissau. Hepatitis B is a severe liver infection, and mother-to-child transmission at birth is the most common route to lifelong infection, with approximately 90% of newborns infected during childbirth becoming chronic carriers. These chronic carriers face a high risk of developing cirrhosis and liver cancer. In Guinea-Bissau, an estimated over 12% of adults live with chronic hepatitis B, and the infection rate in children under five (around 2% in 2020) far exceeds the global target of ≤0.1%. The hepatitis B birth dose vaccine has been recognized by the WHO as an effective and essential public health intervention for over three decades, preventing 70-95% of mother-to-child transmission cases. Over 115 countries have incorporated it into their national immunization schedules. Furthermore, Guinea-Bissau itself formally decided in 2024 to add the hepatitis B birth dose to its national schedule, with introduction planned by 2028, underscoring the vaccine's value and the ethical imperative to provide timely protection to newborns. The core controversy stems from the trial's design, where half of the 14,000 enrolled newborns would not receive the hepatitis B birth dose vaccine, delaying their first dose until six weeks of age or later. WHO Director-General Dr. Tedros Adhanom Ghebreyesus unequivocally stated that the trial is "unethical." He emphasized that withholding a safe and effective vaccine for over 40 years from half of the children in a country with high hepatitis B prevalence violates basic ethical protocols for medical research and could expose infants to a high chance of infection and serious, potentially irreversible harm, including chronic infection, cirrhosis, and liver cancer. The WHO further argues that placebo or no-treatment vaccine trials are only acceptable when no proven intervention exists, or when such a design is indispensable for answering a critical question of efficacy or safety – conditions not met by this study. Some experts have even drawn parallels between the trial's design and historical ethical breaches like the Tuskegee experiment. The US Centers for Disease Control and Prevention (CDC) approved a five-year, $1.6 million grant to a Danish research group, the Bandim Health Project, affiliated with the University of Southern Denmark, to conduct this study. The trial has been linked to Robert F. Kennedy Jr., the current US Health Secretary, who is a well-known vaccine skeptic. An advisory panel appointed by Kennedy recently voted to stop recommending a hepatitis B vaccine for all American newborns. The Danish researchers, Christine Stabell Benn and Peter Aaby, have faced persistent criticism from fellow scientists for their work questioning vaccine effects and have been cited by anti-vaccine activists. The status of the trial has been a source of confusion and conflicting reports. While officials from the Africa Centres for Disease Control and Prevention (Africa CDC) initially stated that the study had been cancelled due to ethical concerns, US health officials, including a spokesperson for the US Department of Health and Human Services (HHS), maintained that the study was "proceeding as planned" and that protocols were still being finalized. However, on January 22, 2026, the Guinea-Bissau government officially suspended the study pending a further ethical review, citing procedural issues with the local ethics approval process. Africa CDC Director-General Jean Kaseya supported this ethical review, emphasizing African health authorities' commitment to ensuring research aligns with the interests of their people. This dynamic highlights the challenges of navigating research ethics, national sovereignty, and global health policy, particularly when controversial funding and research designs are involved. This news is highly relevant to an Indian audience as it underscores critical issues in global health ethics, the importance of robust oversight in vaccine trials, and the potential impact of vaccine skepticism on public health interventions worldwide. India, as a major player in global health and vaccine manufacturing, shares similar concerns regarding equitable access to proven health interventions and ethical research practices in developing nations. The controversy serves as a cautionary tale for all countries involved in international health research, emphasizing the need for transparent, ethical, and scientifically sound protocols that prioritize the well-being of participants, especially vulnerable populations like newborns.

Frequently Asked Questions

Read Full Story on Quick Digest